NCT02202213View on ClinicalTrials.gov

Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

February 28, 2015

Conditions
Schizophrenia
Interventions
DRUG

Placebo

DRUG

Lu AF11167

Trial Locations (1)

91206

Parexel International, Glendale

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT02202213 - Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia | Biotech Hunter | Biotech Hunter